

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



12th February 2019

To,

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051

Scrip Code : 524518

Name of Scrip : KREBSBIO

Dear Sir / Madam,

Sub : Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [“SEBI LODR Regulations”], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. February 12, 2019 :

- (a) The unaudited financial results for the quarter ended 31st December 2018 along with the Limited Review Report thereon (Enclosed herewith).
- (b) Re-appointment of M/s D S M R and Associates, Practicing Company Secretaries as Secretarial Auditors of the company for the FY 2018-19.


Kindly note that the meeting was commenced at 02:30 PM and concluded at 04:40 PM.

You are requested to take note of the above.

Thanking you,

Yours faithfully,
For **Krebs Biochemicals & Industries Limited**


Haritha Varanasi
Company Secretary



CIN: L24110AP1991PLC103912

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

(Rs. In Lacs)

		Quarter Ended			Nine Months Ended		Year Ended
Sl.No	Particulars	31.12.2018 (Un Audited)	30.09.2018 (Un Audited)	31.12.2017 (Un Audited)	31.12.2018 (Un Audited)	31.12.2017 (Un Audited)	31.03.2018 (Audited)
	PART - 1						
1	Revenue from Operations						
	a) Net Sales/Income from Operations	934.87	1272.13	1578.50	2861.75	1882.04	2538.24
	b) Other Operating Income	199.48	303.59	363.12	743.00	580.86	839.67
2	Other Income	12.36	1.47	1.15	16.83	5.18	20.61
3	Total Income (1+2)	1146.71	1,577.19	1,942.77	3,621.58	2,468.08	3,398.52
4	Expenses						
	a) Cost of Materials Consumed	704.38	845.61	963.41	1,664.26	1,178.29	1,712.36
	b) Changes in Inventories of Finished Goods, Work-In-Progress	(109.05)	(115.54)	(224.60)	114.61	(314.52)	(441.83)
	c) Employee Benefits Expenses	412.63	353.24	309.92	1,105.89	748.93	1,148.53
	d) Finance Costs	145.94	145.74	141.78	434.07	376.39	516.52
	e) Depreciation and Amortisation Expenses	107.37	107.37	101.86	322.12	305.57	414.97
	f) Other Manufacturing Expenses	440.85	453.58	428.72	1,198.91	845.04	1,320.57
	g) Other Expenses	90.99	94.59	104.62	261.97	271.74	388.46
	Total Expenses (4)	1,793.11	1,884.59	1,825.71	5,101.83	3,411.44	5,059.58
5	Profit / (Loss) before exceptional items and tax (3±4)	(646.40)	(307.40)	117.06	(1,480.25)	(943.36)	(1,661.06)
6	Exceptional Items:						
	a) Depletion in Value of Inventory	-	-	(72.82)	-	(95.35)	(95.35)
	b) Amounts Written Back	-	-	-	-	-	(0.89)
	c) Prior Period Income/(Expenditure)	-	-	-	-	3.56	(40.03)
	d) Profit on sale of Fixed Assets						14.83
7	Profit / (Loss) before Tax (5±6)	(646.40)	(307.40)	44.24	(1,480.25)	(1,035.15)	(1,782.49)
8	Tax Expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	Profit / (Loss) for the period (7±8)	(646.40)	(307.40)	44.24	(1,480.25)	(1,035.15)	(1,782.49)
10	Other Comprehensive Income	(27.43)	(25.43)	(23.50)	(79.45)	(66.75)	(143.12)
11	Total Comprehensive Income for the period(9±10) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	(673.83)	(332.83)	20.74	(1,559.70)	(1,101.90)	(1,925.61)
12	Paid-up equity share capital (Face value of Rs 10/- each)	1,374.43	1,374.43	1,374.43	1,374.43	1,374.43	1,374.43
13	Other Equity						(3,152.35)
14	Earning Per Share (of Rs.10/- each) (not Annualised):						
	a) Basic	(4.90)	(2.42)	0.15	(11.35)	(8.02)	(14.01)
	b) Diluted	(4.90)	(2.42)	0.15	(11.35)	(8.02)	(14.01)
	See accompanying notes to the Financial results						
1	The above results have been reviewed by the Audit Committee at its meeting held on 12th February 2019 and approved by the Board of Directors of the Company at its meeting held on 12th February 2019. The results are subjected to limited review by statutory auditors.						
2	The Company is operating in one segment only hence no segment results have been disclosed.						
3	Post implementation of GST wef 1st July 2017, revenues are disclosed net of GST. Revenue for the period prior to 1st July 2017 included Excise Duty which is now subsumed in GST. Accordingly, revenue for the Nine Months ended 31st December 2017 and Year ended 31st March 2018 are not comparable with those of the other periods presented.						
4	The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.						



Avinash Ravi
 Managing Director
 DIN: 0161615X

Place : Hyderabad

Date : 12.02.2019



PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
Micasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

Limited Review Report

**Review Report to
The Board of Directors,
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **31st December, 2018** and the year to date from 1st April 2018 to 31st December 2018 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S


(CA. N. RAJESH)
PARTNER
M.No: 223169



Place: Hyderabad
Date: 12.02.2019